Transporter-mediated drug uptake and efflux: Important determinants of adverse drug reactions

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 6, 2011, Pages 798-805

  Zolk, O ^a   Fromm, M F ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ADEFOVIR; ATORVASTATIN; BOSENTAN; CARBOPLATIN; CIDOFOVIR; CIMETIDINE; CISPLATIN; CYCLOSPORIN; DIGOXIN; EVEROLIMUS; FUROSEMIDE; GLIBENCLAMIDE; IRINOTECAN; LAMIVUDINE; LOPERAMIDE; METFORMIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXALIPLATIN; PRAVASTATIN; PROBENECID; RAPAMYCIN; RIFAMPICIN; SIMVASTATIN; TACROLIMUS; TENOFOVIR; TOPOTECAN; TROGLITAZONE; UNINDEXED DRUG;

ADVERSE OUTCOME; ANEMIA; BASOLATERAL MEMBRANE; BILIARY EXCRETION; BLOOD BRAIN BARRIER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TRANSPORT; DRUG UPTAKE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEARING LOSS; HEPATITIS B; HEREDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; IN VITRO STUDY; INFECTION; INTRAHEPATIC CHOLESTASIS; KIDNEY; KIDNEY DYSFUNCTION; KIDNEY INJURY; LACTIC ACIDOSIS; LEUKOPENIA; LIVER; LIVER CELL; LIVER INJURY; LIVER METABOLISM; MYOPATHY; NAUSEA; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OTOTOXICITY; PERIPHERAL NEUROPATHY; PORTAL VEIN BLOOD; PRIORITY JOURNAL; PROTEIN MODIFICATION; RESPIRATION DEPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SMALL INTESTINE; STEADY STATE; THROMBOCYTOPENIA; VOMITING;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD-BRAIN BARRIER; DRUG TOXICITY; HUMANS; INTESTINE, SMALL; KIDNEY; LIVER; MEMBRANE TRANSPORT PROTEINS; PHARMACEUTICAL PREPARATIONS;

EID: 79956326438     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.354     Document Type: Review

References (52)

1. Fromm, M.F., Kim, R.B., Stein, C.M., Wilkinson, G.R. & Roden, D.M. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 99, 552-557 (1999). (Pubitemid 29061872)
2. Niemi, M. Transporter pharmacogenetics and statin toxicity. Clin. Pharmacol. Ther. 87, 130-133 (2010).
3. Neuvonen, P.J. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, Transporters and pharmacogenetics. Curr. Opin. Investig. Drugs 11, 323-332 (2010).
4. Tirona, R.G., Leake, B.F., Merino, G. & Kim, R.B. Polymorphisms in OATP-C: identifcation of multiple allelic variants associated with altered transport activity among European- and African-Americans. J. Biol. Chem. 276, 35669-35675 (2001).
5. Fahrmayr, C., Fromm, M.F. & König, J. Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects. Drug Metab. Rev. 42, 380-401 (2010).
6. Pasanen, M.K., Neuvonen, M., Neuvonen, P.J. & Niemi, M. SLCO1B1 polymorphism markedly afects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics 16, 873-879 (2006). (Pubitemid 44772805)
7. Link, E. et al.; SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med. 359, 789-799 (2008).
8. Voora, D. et al. The SLCO1B1*5 genetic variant is associated with statin-induced side efects. J. Am. Coll. Cardiol. 54, 1609-1616 (2009).
9. Knauer, M.J. et al. Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ. Res. 106, 297-306 (2010).
10. Picard, N. et al. The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin. Pharmacol. Ther. 87, 100-108 (2010).
11. Michelon, H. et al. SLCO1B1 genetic polymorphism infuences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics 11, 1703-1713 (2010).
12. Wang, D.S., Kusuhara, H., Kato, Y., Jonker, J.W., Schinkel, A.H. & Sugiyama, Y. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol. Pharmacol. 63, 844-848 (2003). (Pubitemid 36368991)
13. Shu, Y. et al. Efect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 117, 1422-1431 (2007). (Pubitemid 46718430)
14. Russmann, S., Jetter, A. & Kullak-Ublick, G.A. Pharmacogenetics of drug-induced liver injury. Hepatology 52, 748-761 (2010).
15. Pauli-Magnus, C., Meier, P.J. & Stieger, B. Genetic determinants of drug-induced cholestasis and intrahepatic cholestasis of pregnancy. Semin. Liver Dis. 30, 147-159 (2010).
16. Lang, C. et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet. Genomics 17, 47-60 (2007). (Pubitemid 46183791)
17. El-Sheikh, A.A., Masereeuw, R. & Russel, F.G. Mechanisms of renal anionic drug transport. Eur. J. Pharmacol. 585, 245-255 (2008).
18. Hulot, J.S. et al. A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet. Genomics 15, 277-285 (2005).
19. Vlaming, M.L. et al. Abcc2 (Mrp2), Abcc3 (Mrp3), And Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Mol. Cancer Ther. 8, 3350-3359 (2009).
20. Takane, H., Shikata, E., Otsubo, K., Higuchi, S. & Ieiri, I. Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics 9, 415-422 (2008). (Pubitemid 351803926)
21. König, J., Zolk, O., Singer, K., Hofmann, C. & Fromm, M. Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations. Br. J. Pharmacol. (2010); e-pub ahead of print 30 Sep 2010.
22. Li, Q., Liu, F., Zheng, T.S., Tang, J.L., Lu, H.J. & jia, W.P. SLC22A2 gene 808 G/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin. Acta Pharmacol. Sin. 31, 184-190 (2010).
23. Filipski, K.K., Mathijssen, R.H., Mikkelsen, T.S., Schinkel, A.H. & Sparreboom, A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin. Pharmacol. Ther. 86, 396-402 (2009).
24. Ciarimboli, G. et al. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am. J. Pathol. 176, 1169-1180 (2010).
25. Yokoo, S., Yonezawa, A., Masuda, S., Fukatsu, A., Katsura, T. & Inui, K. Diferential contribution of organic cation transporters, OCT2 and MATE1, In platinum agent-induced nephrotoxicity. Biochem. Pharmacol. 74, 477-487 (2007). (Pubitemid 46963232)
26. Nakamura, T., Yonezawa, A., Hashimoto, S., Katsura, T. & Inui, K. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem. Pharmacol. 80, 1762-1767 (2010).
27. Naesens, M., Kuypers, D.R. & Sarwal, M. Calcineurin inhibitor nephrotoxicity. Clin. J. Am. Soc. Nephrol. 4, 481-508 (2009).
28. Andoh, T.F., Lindsley, J., Franceschini, N. & Bennett, W.M. Synergistic efects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation 62, 311-316 (1996). (Pubitemid 26277334)
29. Cravedi, P., Ruggenenti, P. & Remuzzi, G. Sirolimus for calcineurin inhibitors in organ transplantation: contra. Kidney Int. 78, 1068-1074 (2010).
30. Del Moral, R.G. et al. Chronic cyclosporin A nephrotoxicity, P-glycoprotein overexpression, And relationships with intrarenal angiotensin II deposits. Am. J. Pathol. 151, 1705-1714 (1997). (Pubitemid 27527933)
31. Joy, M.S., Nickeleit, V., Hogan, S.L., Thompson, B.D. & Finn, W.F. Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoprotein. Pharmacotherapy 25, 779-789 (2005). (Pubitemid 40727128)
32. Hauser, I.A. et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J. Am. Soc. Nephrol. 16, 1501-1511 (2005). (Pubitemid 41716536)
33. Staatz, C.E., Goodman, L.K. & Tett, S.E. Efect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. Clin. Pharmacokinet. 49, 207-221 (2010).
34. Hebert, M.F. et al. Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 13, 661-674 (2003). (Pubitemid 38316510)
35. Izzedine, H., Launay-Vacher, V. & Deray, G. Antiviral drug-induced nephrotoxicity. Am. J. Kidney Dis. 45, 804-817 (2005). (Pubitemid 43181039)
36. Uwai, Y., Ida, H., Tsuji, Y., Katsura, T. & Inui, K. Renal transport of adefovir, Cidofovir, And tenofovir by SLC22A family members (hOAT1, HOAT3, And hOCT2). Pharm. Res. 24, 811-815 (2007). (Pubitemid 46411965)
37. Ho, E.S., Lin, D.C., Mendel, D.B. & Cihlar, T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J. Am. Soc. Nephrol. 11, 383-393 (2000). (Pubitemid 30115068)
38. Servais, A. et al. Tubular transporters and clearance of adefovir. Eur. J. Pharmacol. 540, 168-174 (2006). (Pubitemid 43866711)
39. Cihlar, T., Ho, E.S., Lin, D.C. & Mulato, A.S. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 20, 641-648 (2001). (Pubitemid 32821831)
40. Eberl, S. et al. Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. Clin. Pharmacokinet. 46, 1039-1049 (2007). (Pubitemid 350136910)
41. Urquhart, B.L. & Kim, R.B. Blood-brain barrier transporters and response to CNS-active drugs. Eur. J. Clin. Pharmacol. 65, 1063-1070 (2009).
42. Fromm, M.F. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci. 25, 423-429 (2004). (Pubitemid 38981558)
43. Schinkel, A.H., Wagenaar, E., Mol, C.A. & van Deemter, L. P-glycoprotein in the blood-brain barrier of mice infuences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97, 2517-2524 (1996). (Pubitemid 26187339)
44. Sadeque, A.J., Wandel, C., He, H., Shah, S. & Wood, A.J. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin. Pharmacol. Ther. 68, 231-237 (2000).
45. Pauli-Magnus, C., Feiner, J., Brett, C., Lin, E. & Kroetz, D.L. No efect of MDR1 C3435T variant on loperamide disposition and central nervous system efects. Clin. Pharmacol. Ther. 74, 487-498 (2003). (Pubitemid 37357727)
46. Skarke, C. et al. Efects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous efects of loperamide in healthy volunteers. Pharmacogenetics 13, 651-660 (2003). (Pubitemid 38316509)
47. Vandenbossche, J., Huisman, M., Xu, Y., Sanderson-Bongiovanni, D. & Soons, P. Loperamide and P-glycoprotein inhibition: assessment of the clinical relevance. J. Pharm. Pharmacol. 62, 401-412 (2010).
48. Coller, J.K., Barratt, D.T., Dahlen, K., Loennechen, M.H. & Somogyi, A.A. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin. Pharmacol. Ther. 80, 682-690 (2006). (Pubitemid 44920224)
49. Löscher, W. Drug transporters in the epileptic brain. Epilepsia 48 (suppl. 1), 8-13 (2007). (Pubitemid 46280513)
50. Letrent, S.P., Pollack, G.M., Brouwer, K.R. & Brouwer, K.L. Efect of GF120918, A potent P-glycoprotein inhibitor, On morphine pharmacokinetics and pharmacodynamics in the rat. Pharm. Res. 15, 599-605 (1998). (Pubitemid 28214954)
51. Hubensack, M. et al. Efect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. J. Cancer Res. Clin. Oncol. 134, 597-607 (2008). (Pubitemid 351422612)
52. Drewe, J. et al. Efect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse efects of morphine. Br. J. Clin. Pharmacol. 50, 237-246 (2000).